Found Medical Leadership and Credentials: An Independent Review

Who Leads Found's Medical Team?

Found's most prominent clinical figure is Dr. Rekha Kumar, a board-certified endocrinologist and obesity medicine specialist. She joined as Chief Medical Officer in 2022 after serving as medical director of the American Board of Obesity Medicine (ABOM). Her academic appointment at Weill Cornell Medicine and her published work on pharmacotherapy for obesity give her credentials that hold up to scrutiny.

Dr. Rekha Kumar's Specific Qualifications

Dr. Kumar is dual board-certified in endocrinology and obesity medicine. ABOM certification requires passing a rigorous exam, demonstrating at least 60 hours of continuing medical education in obesity, and maintaining active clinical practice. The ABOM exam pass rate hovers near 60%, making the credential meaningfully selective.

Her published research includes work on GLP-1 receptor agonists and insulin resistance. She has written for peer-reviewed journals indexed in PubMed and has spoken at the Obesity Society's annual meetings. That public record is verifiable and distinguishes her from CMOs at some competitor platforms whose credentials are harder to confirm.

The Gap Between Leadership and Front-Line Prescribing

A CMO's credentials matter, but so does how those credentials translate into actual patient care. Found operates at scale, serving hundreds of thousands of members. At that volume, a single CMO cannot review individual prescriptions. The practical question is whether the physicians, nurse practitioners, and physician assistants writing actual prescriptions are supervised adequately.

Found has not published a full roster of its prescribing clinicians with individual state-board license numbers. Patients in states like Texas, Florida, and California can verify a prescriber's license through their state medical board, but Found's platform does not make the prescriber's name consistently visible before the prescription is sent. This is a transparency gap that competitors like Hims & Hers and Ro have partially closed by displaying prescriber names on order confirmations.

How Found Prescribes GLP-1 Medications

Found prescribes several anti-obesity medications, including GLP-1 receptor agonists (semaglutide, tirzepatide), bupropion/naltrexone (Contrave), and phentermine-based combinations. Each drug class carries distinct regulatory and safety requirements.

GLP-1 Receptor Agonists: Clinical Evidence and Prescribing Standards

The evidence base for GLP-1 receptor agonists is well established. In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) (Wilding et al., NEJM 2021). The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieving 20.9% mean weight reduction at 72 weeks versus 3.1% with placebo (Jastreboff et al., NEJM 2022).

These outcomes require proper patient selection. The FDA label for semaglutide 2.4 mg (Wegovy) specifies use in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (FDA prescribing information). Found's intake questionnaire asks about BMI and comorbidities, but it does so asynchronously, without a live clinical interview in most cases. Whether that intake adequately screens for contraindications, including personal or family history of medullary thyroid carcinoma or MEN2, depends on the thoroughness of the algorithm and the reviewing clinician's diligence.

Controlled Substances and DEA Compliance

Phentermine is a Schedule IV controlled substance. Under the Ryan Haight Online Pharmacy Consumer Protection Act, prescribing a controlled substance via telemedicine generally requires at least one in-person medical evaluation before the prescription is issued, with narrow exceptions (DEA, 21 U.S.C. § 831). The DEA's 2023 telemedicine rules created a limited exception for audio-visual appointments, but many states layer additional requirements on top of federal law.

Found acknowledges on its platform that phentermine prescribing is state-dependent. However, the platform does not clearly tell prospective members upfront which states allow phentermine via its model and which require a referral to an in-person provider. Clarity here would reduce the risk of patients receiving a prescription that a state board later classifies as improperly issued.

Compounded Semaglutide and Tirzepatide

During the FDA drug shortage periods for Wegovy and Zepbound (2022 through mid-2024), Found, like many telehealth platforms, prescribed compounded semaglutide and tirzepatide from 503A and 503B pharmacies. The FDA removed semaglutide from its drug shortage list in October 2024, and the agency has signaled that compounding of GLP-1 drugs based on shortage status alone is no longer permitted (FDA, March 2025). Prescribers who continue ordering compounded GLP-1s without a documented patient-specific medical justification face regulatory exposure. Found has not published a public statement clarifying its current policy on compounded GLP-1 prescribing.

Insurance Coverage: The BCBS Partnership

Found has partnered with Blue Cross Blue Shield plans in select markets to cover its membership fee and, in some cases, the medication costs. This is a meaningful differentiator. Most telehealth weight-loss platforms operate on a cash-pay model, putting GLP-1 medications out of reach for patients who cannot afford $900 to $1,300 per month out of pocket.

What the BCBS Partnership Actually Covers

The BCBS partnership coverage varies by plan and state. In some markets, the partnership covers only Found's monthly membership fee (roughly $99 per month), not the medication itself. In others, it counts toward the member's in-network benefits for obesity treatment, which can reduce GLP-1 costs substantially.

The American Heart Association and the American College of Cardiology both support treating obesity as a chronic disease requiring long-term pharmacotherapy when lifestyle intervention alone is insufficient (AHA/ACC Guideline, Circulation 2021). Insurance coverage that makes this pharmacotherapy accessible serves a genuine public health need. Found's BCBS deal moves the platform in that direction, even if the coverage is inconsistent across markets.

Limitations of the Insurance Model

Found's insurance integration does not yet include real-time prior authorization support for patients whose plans require it before dispensing semaglutide or tirzepatide. Patients in these plans may go through Found's intake, receive a prescription, and then discover the pharmacy will not fill it without a PA that Found's care team has not yet initiated. This is a workflow gap that affects patient trust more than it affects clinical safety, but it generates the type of complaint that surfaces repeatedly on the Better Business Bureau and Trustpilot.

Is Found Legit? Licensing, Accreditation, and Complaints

State Medical Board and Pharmacy Compliance

Found operates as a telehealth platform, meaning its prescribing clinicians must hold active, unrestricted licenses in the states where they see patients. The platform is not a licensed pharmacy; it routes prescriptions to third-party pharmacies including Truepill (now Postmeds) and others. State pharmacy boards regulate the dispensing side independently.

Found has not been cited for unlicensed prescribing in any publicly available state medical board action as of this review. That is a positive finding, but the absence of a citation is different from affirmative transparency. A platform that publishes its prescriber roster, license numbers, and supervising physician agreements for mid-level practitioners gives patients and regulators a cleaner audit trail.

BBB Profile and Consumer Complaints

Found is not BBB-accredited. Its BBB profile shows a pattern of complaints in three categories: billing disputes (charges continuing after cancellation), delays in prescription fulfillment, and difficulty reaching a human clinician when a patient has a clinical question.

The billing complaints are the most numerous. Patients report that canceling a Found membership requires navigating a multi-step process, and that charges sometimes continue for one to two billing cycles after cancellation is requested. This is a consumer protection issue, not a clinical safety issue, but it affects whether patients trust the platform enough to stay engaged with their treatment long enough to see clinical benefit.

Clinical safety complaints are fewer but worth noting. A small number of BBB reports describe patients experiencing adverse effects (nausea, vomiting, tachycardia) who could not reach a clinician promptly through Found's messaging system. GLP-1 adverse effects are common: in STEP-1, nausea occurred in 44% of semaglutide participants versus 16% on placebo (Wilding et al., NEJM 2021). A platform prescribing these drugs at scale needs a clinical triage pathway that can respond to symptom reports within a defined timeframe. Found does not publicly specify its response-time standard for clinical messages.

LegitScript Certification Status

LegitScript is the third-party verification service that Google, Meta, and major payment processors require telehealth platforms to pass before advertising prescription drug services. LegitScript evaluates licensing, prescribing practices, and pharmacy affiliations. Found holds LegitScript certification for its telehealth services, which is a meaningful quality signal. Platforms that cannot pass LegitScript review are barred from running paid ads on Google and cannot process payments through many financial institutions.

The table below organizes the key credential and compliance indicators for Found against the standards a patient or clinician reviewer should apply.

| Indicator | Found's Status | Standard | |---|---|---| | Named CMO with verifiable credentials | Yes (Dr. Rekha Kumar, ABOM-certified) | Required | | Full prescriber roster published | No | Best practice | | LegitScript certified | Yes | Required for advertising | | BBB accreditation | No | Optional but relevant | | State board actions on record | None found | Desired: zero | | Compounded GLP-1 policy published | No | Needed post-2024 FDA guidance | | Clinical message response SLA | Not disclosed | Best practice: <24 hours |

Clinical Protocols and Care Quality

Intake and Screening Process

Found's intake is fully digital. Patients complete a health history questionnaire, submit weight and height, and may optionally upload lab work. A clinician reviews the intake asynchronously and either approves a prescription or sends follow-up questions through the platform's messaging system.

The American Association of Clinical Endocrinology (AACE) and the Obesity Medicine Association both recommend a medical evaluation that includes a history, physical examination findings, and review of relevant labs before initiating anti-obesity pharmacotherapy (AACE Obesity Clinical Practice Guidelines, 2016). Found's asynchronous model satisfies the history component but cannot satisfy a physical examination in the traditional sense. For most healthy adults seeking GLP-1 therapy for straightforward obesity without complex comorbidities, this gap is small. For patients with uncontrolled hypertension, a history of pancreatitis, or active eating disorders, the gap is clinically meaningful.

Ongoing Monitoring Standards

GLP-1 receptor agonists require periodic follow-up to assess efficacy, tolerability, and dose titration. Found's care model includes scheduled check-ins, but these are asynchronous by default. Patients can request a synchronous (video) appointment for an additional fee in some markets.

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy states: "We recommend that clinicians monitor patients on anti-obesity medications at least monthly for the first three months, then at least quarterly thereafter, to assess response and tolerability" (Apovian et al., J Clin Endocrinol Metab 2015). Found's messaging-based check-in model can technically fulfill this frequency requirement, but the quality of an asynchronous check-in is lower than a synchronous encounter for detecting subtle adverse effects or assessing the need for dose adjustment.

Medication Titration and Safety Protocols

The FDA-approved semaglutide titration schedule for Wegovy starts at 0.25 mg weekly for four weeks, increasing stepwise to the 2.4 mg maintenance dose over 16 to 20 weeks. Found follows this schedule in its published dosing guidance, which is consistent with the label. Whether individual prescribers deviate from this schedule based on patient-reported tolerability, and whether deviations are documented and supervised, is not visible to outside reviewers.

What Patients Should Verify Before Enrolling

Patients considering Found should take four specific steps before submitting payment or completing intake.

First, ask for the name and license number of the clinician who will review your intake. You can verify that license at your state medical board's website within minutes. If Found cannot or will not provide this information before you pay, that is a yellow flag.

Second, confirm whether your specific insurance plan covers Found's membership fee, the medication, or both. Get this in writing from Found's support team, not just from the website's general language about BCBS partnerships.

Third, ask Found directly about its current policy on compounded semaglutide or tirzepatide. If the platform is still offering compounded GLP-1 drugs without a documented clinical justification for why the brand-name product is unsuitable for you specifically, the prescribing may not align with the FDA's post-shortage guidance.

Fourth, review Found's cancellation policy before entering your payment details. The BBB complaint pattern on billing is consistent enough to warrant reading the cancellation terms carefully and keeping a timestamped record of any cancellation request.

A patient with a BMI of 33 kg/m² and type 2 diabetes who wants semaglutide 2.4 mg and whose BCBS plan covers Found is a good candidate for the platform. A patient with a history of pancreatitis, a complex medication list, or significant cardiac history should insist on a synchronous clinical evaluation, either through Found's video option or through an in-person provider.